Regenxbio (RGNX) Operating Expenses (2014 - 2025)

Regenxbio's Operating Expenses history runs 12 years deep, the most recent figure standing at $9.6 million for Q4 2025.

• On a quarterly basis, Operating Expenses fell 86.82% year-over-year to $9.6 million in Q4 2025; TTM through Dec 2025 was $176.2 million, a 44.35% decrease from a year earlier, with the FY2025 full-year figure at $32.9 million, down 89.62% from the prior year.
• Operating Expenses declined to $9.6 million in Q4 2025 per RGNX's latest filing, from $82.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $97.6 million in Q3 2022 and bottomed at -$275.7 million in Q4 2022.
• The 5-year median for Operating Expenses is $83.6 million (2021), against an average of $58.6 million.
• Across the five-year window, Operating Expenses slumped 424.15% in 2022 and soared 131.23% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $85.1 million in 2021, then slumped by 424.15% to -$275.7 million in 2022, then surged by 131.23% to $86.1 million in 2023, then slipped by 15.72% to $72.6 million in 2024, then plunged by 86.82% to $9.6 million in 2025.
• Per Business Quant, the three latest RGNX Operating Expenses figures stand at $9.6 million (Q4 2025), $82.1 million (Q3 2025), and $7.6 million (Q2 2025).